Cargando…

Modified Sijunzi Decoction Inhibits Epithelial-Mesenchymal Transition of Non-Small Cell Lung Cancer by Attenuating AKT/GSK3β Pathway in vitro and in vivo

Modified Sijunzi Decoction (MSJZD) is an empirical prescription of Traditional Chinese Medicine (TCM) and has been corroborated to be effective in multiple human diseases, but its role in non-small cell lung cancer (NSCLC) is enigmatic. Here we mainly analyze the function and mechanism of MSJZD in N...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Niu, Xiao, Yao, Zhang, Jiaxin, Zhu, Yuying, Wang, Shenglong, Bao, Suzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802809/
https://www.ncbi.nlm.nih.gov/pubmed/35111070
http://dx.doi.org/10.3389/fphar.2021.821567
_version_ 1784642749578870784
author Shao, Niu
Xiao, Yao
Zhang, Jiaxin
Zhu, Yuying
Wang, Shenglong
Bao, Suzhen
author_facet Shao, Niu
Xiao, Yao
Zhang, Jiaxin
Zhu, Yuying
Wang, Shenglong
Bao, Suzhen
author_sort Shao, Niu
collection PubMed
description Modified Sijunzi Decoction (MSJZD) is an empirical prescription of Traditional Chinese Medicine (TCM) and has been corroborated to be effective in multiple human diseases, but its role in non-small cell lung cancer (NSCLC) is enigmatic. Here we mainly analyze the function and mechanism of MSJZD in NSCLC. In this study, we used a method that coupled ultra-performance liquid chromatography to quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS) to investigate the major constituents in MSJZD with positive and negative ion modes. Additionally, in in vitro experiments, the effects of serum-containing MSJZD on the biological behavior of NSCLC cells induced by TGF-β1 were assessed by cell function experiments. Then, the influences of serum-containing MSJZD on epithelial-mesenchymal transition (EMT)-related markers were examined by immunofluorescence and western blot assays. Also, the AKT/GSK3β pathway and apoptosis-related markers were estimated by western blotting. Tumor xenografts were generated by subcutaneously injecting A549 cells into BALB/c nude mice to determine the effects of MSJZD in vivo. We first analyzed the composition of MSJZD. In positive ion mode, 47 kinds of components were identified. In negative ion mode, 45 kinds of components were identified. We also found that TGF-β1 contributed to inducing cell morphological changes and EMT progression. In vitro, surprisingly, cell proliferation, migration as well as invasion in NSCLC cells induced by TGF-β1, could be weakened by serum-containing MSJZD, and apoptosis was intensified. Moreover, serum-containing MSJZD weakened EMT passage and AKT/GSK3β pathway activation and induced apoptosis-related markers in NSCLC cells triggered by TGF-β1. In vivo, we discovered that MSJZD attenuated the tumor growth, promoted histopathological damage, and induced apoptosis in A549 tumor-bearing mice. Importantly, MSJZD has also restrained the development of EMT, AKT/GSK3β pathway, and TGF-β1 expression levels in nude mice. These findings demonstrated that MSJZD significantly weakened NSCLC progression by modulating EMT and AKT/GSK3β pathway.
format Online
Article
Text
id pubmed-8802809
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88028092022-02-01 Modified Sijunzi Decoction Inhibits Epithelial-Mesenchymal Transition of Non-Small Cell Lung Cancer by Attenuating AKT/GSK3β Pathway in vitro and in vivo Shao, Niu Xiao, Yao Zhang, Jiaxin Zhu, Yuying Wang, Shenglong Bao, Suzhen Front Pharmacol Pharmacology Modified Sijunzi Decoction (MSJZD) is an empirical prescription of Traditional Chinese Medicine (TCM) and has been corroborated to be effective in multiple human diseases, but its role in non-small cell lung cancer (NSCLC) is enigmatic. Here we mainly analyze the function and mechanism of MSJZD in NSCLC. In this study, we used a method that coupled ultra-performance liquid chromatography to quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS) to investigate the major constituents in MSJZD with positive and negative ion modes. Additionally, in in vitro experiments, the effects of serum-containing MSJZD on the biological behavior of NSCLC cells induced by TGF-β1 were assessed by cell function experiments. Then, the influences of serum-containing MSJZD on epithelial-mesenchymal transition (EMT)-related markers were examined by immunofluorescence and western blot assays. Also, the AKT/GSK3β pathway and apoptosis-related markers were estimated by western blotting. Tumor xenografts were generated by subcutaneously injecting A549 cells into BALB/c nude mice to determine the effects of MSJZD in vivo. We first analyzed the composition of MSJZD. In positive ion mode, 47 kinds of components were identified. In negative ion mode, 45 kinds of components were identified. We also found that TGF-β1 contributed to inducing cell morphological changes and EMT progression. In vitro, surprisingly, cell proliferation, migration as well as invasion in NSCLC cells induced by TGF-β1, could be weakened by serum-containing MSJZD, and apoptosis was intensified. Moreover, serum-containing MSJZD weakened EMT passage and AKT/GSK3β pathway activation and induced apoptosis-related markers in NSCLC cells triggered by TGF-β1. In vivo, we discovered that MSJZD attenuated the tumor growth, promoted histopathological damage, and induced apoptosis in A549 tumor-bearing mice. Importantly, MSJZD has also restrained the development of EMT, AKT/GSK3β pathway, and TGF-β1 expression levels in nude mice. These findings demonstrated that MSJZD significantly weakened NSCLC progression by modulating EMT and AKT/GSK3β pathway. Frontiers Media S.A. 2022-01-17 /pmc/articles/PMC8802809/ /pubmed/35111070 http://dx.doi.org/10.3389/fphar.2021.821567 Text en Copyright © 2022 Shao, Xiao, Zhang, Zhu, Wang and Bao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Shao, Niu
Xiao, Yao
Zhang, Jiaxin
Zhu, Yuying
Wang, Shenglong
Bao, Suzhen
Modified Sijunzi Decoction Inhibits Epithelial-Mesenchymal Transition of Non-Small Cell Lung Cancer by Attenuating AKT/GSK3β Pathway in vitro and in vivo
title Modified Sijunzi Decoction Inhibits Epithelial-Mesenchymal Transition of Non-Small Cell Lung Cancer by Attenuating AKT/GSK3β Pathway in vitro and in vivo
title_full Modified Sijunzi Decoction Inhibits Epithelial-Mesenchymal Transition of Non-Small Cell Lung Cancer by Attenuating AKT/GSK3β Pathway in vitro and in vivo
title_fullStr Modified Sijunzi Decoction Inhibits Epithelial-Mesenchymal Transition of Non-Small Cell Lung Cancer by Attenuating AKT/GSK3β Pathway in vitro and in vivo
title_full_unstemmed Modified Sijunzi Decoction Inhibits Epithelial-Mesenchymal Transition of Non-Small Cell Lung Cancer by Attenuating AKT/GSK3β Pathway in vitro and in vivo
title_short Modified Sijunzi Decoction Inhibits Epithelial-Mesenchymal Transition of Non-Small Cell Lung Cancer by Attenuating AKT/GSK3β Pathway in vitro and in vivo
title_sort modified sijunzi decoction inhibits epithelial-mesenchymal transition of non-small cell lung cancer by attenuating akt/gsk3β pathway in vitro and in vivo
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802809/
https://www.ncbi.nlm.nih.gov/pubmed/35111070
http://dx.doi.org/10.3389/fphar.2021.821567
work_keys_str_mv AT shaoniu modifiedsijunzidecoctioninhibitsepithelialmesenchymaltransitionofnonsmallcelllungcancerbyattenuatingaktgsk3bpathwayinvitroandinvivo
AT xiaoyao modifiedsijunzidecoctioninhibitsepithelialmesenchymaltransitionofnonsmallcelllungcancerbyattenuatingaktgsk3bpathwayinvitroandinvivo
AT zhangjiaxin modifiedsijunzidecoctioninhibitsepithelialmesenchymaltransitionofnonsmallcelllungcancerbyattenuatingaktgsk3bpathwayinvitroandinvivo
AT zhuyuying modifiedsijunzidecoctioninhibitsepithelialmesenchymaltransitionofnonsmallcelllungcancerbyattenuatingaktgsk3bpathwayinvitroandinvivo
AT wangshenglong modifiedsijunzidecoctioninhibitsepithelialmesenchymaltransitionofnonsmallcelllungcancerbyattenuatingaktgsk3bpathwayinvitroandinvivo
AT baosuzhen modifiedsijunzidecoctioninhibitsepithelialmesenchymaltransitionofnonsmallcelllungcancerbyattenuatingaktgsk3bpathwayinvitroandinvivo